Bladder Cancer - Pipeline Insight, 2024

Bladder Cancer - Pipeline Insight, 2024

DelveInsight’s, “Bladder Cancer - Pipeline Insight, 2024,”report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Bladder Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Bladder Cancer Understanding

Bladder Cancer: Overview

Bladder cancer is a disease that usually begins in the cells that line the inside of the bladder. It typically affects people older than 70 and occurs more often in men. Bladder cancer is the fifth most common form of cancer overall and the fourth most common among men. Bladder cancer usually responds well to treatment when diagnosed early. However, people who have been successfully treated for bladder cancer should be monitored afterward. Bladder cancer can return even years later. About 90 percent of bladder cancers begin in the cells on the surface of the bladder’s inner lining. This type of cancer is called urothelial carcinoma (also called transitional cell carcinoma). Most urothelial carcinoma is non-muscle invasive. That means the cancer stays within the bladder’s inner lining. Less common types of bladder cancer include squamous cell carcinoma, adenocarcinoma, and small cell carcinoma. These types can develop in the inner lining as a result of chronic irritation and inflammation. They usually grow into the muscle of the bladder over time.

In most cases, the first sign of bladder cancer is blood in the urine. Other symptoms may include feeling pain or burning during urination or a change in urination habits. This can include frequent urination or a need to go but being unable to pass urine. More-advanced bladder cancer may involve lower back pain on one side, feeling tired or weak, or having no appetite and losing weight. Tobacco use is by far the biggest risk factor for developing bladder cancer. People who smoke cigarettes are up to four times more likely than nonsmokers to develop the disease. Studies have shown that smoking is responsible for approximately 50 percent of bladder cancers.

Tests and procedures used to diagnose bladder cancer may include using a scope to examine the inside of bladder Cystoscopy, Biopsy, urine cytology, imaging tests in case of confirmation of the cancer in the body other tests are also done that includes CT Scan, MRI, PET, Bone Scan, Chest X ray. Treatment options for bladder cancer depend on a number of factors, including the type of cancer, grade of the cancer and stage of the cancer, which are taken into consideration along with the overall health of patient. Bladder cancer treatment may include: Surgery, to remove the cancer cells, Chemotherapy in the bladder (intravesical chemotherapy), Chemotherapy for the whole body (systemic chemotherapy), Radiation therapy, to destroy cancer cells, often as a primary treatment, Immunotherapy, to trigger the body's immune system to fight cancer cells, Targeted therapy, to treat advanced cancer.

""Bladder Cancer - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bladder Cancer pipeline landscape is provided which includes the disease overview and Bladder Cancer treatment guidelines. The assessment part of the report embraces, in depth Bladder Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bladder Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Bladder Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Colorectal Cancer.

Bladder Cancer Emerging Drugs Chapters

This segment of the Bladder Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bladder Cancer Emerging Drugs

• UGN-102: UroGen Pharma Ltd.

UGN-102 (mitomycin) for intravesical solution is an investigational drug formulation of mitomycin. It is been developed by utilizing UroGen’s proprietary RTGel® technology which is a sustained release, hydrogel-based formulation, UGN-102 is designed to enable longer exposure of bladder tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means. UGN-102 is delivered to patients using a standard urinary catheter in an outpatient setting. Currently it is in Phase III stage of clinical trial for the treatment of Bladder Cancer.

• APL 1202 : Asieris Pharmaceuticals

APL-1202 is an orally available reversible MetAP2 Inhibitor with anti-angiogenic, anti-tumor activities and can also modulate tumor immune microenvironment. It is currently in registration clinical trials in China, either as single agent as first-line treatment for patients with intermediate-risk non-muscle invasive bladder cancer (NMIBC), or in combination with a chemotherapy as second-line treatment in patients with intermediate and high-risk chemo-refractory NMIBC. Currently, the drug is being evaluated in the Phase III stage for Bladder Cancer.

• Trilaciclib: G1 Therapeutics, Inc.

Trilaciclib, is a first-in-class therapy designed to improve outcomes for people with cancer who are treated with chemotherapy. It is a transient IV-administered CDK4/6 inhibitor, a novel therapeutic approach which is given before chemotherapy that temporarily blocks progression through the cell cycle. Currently the drug is being evaluated in Phase II for the treatment of Bladder Cancer.

• Catumaxomab: LintonPharm Co.,Ltd.

Catumaxomab is a bispecific antibody that binds to EpCAM (the epithelial cell adhesion molecule) on the tumor cell--and CD3 on the T cell, recruits immune accessory cells through FcγR binding at the same time. The drug kills tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models. The drug is in Phase I/II stage of clinical trials for the treatment of bladder cancer.

• VAX 014: Vaxiion Therapeutics

VAX014 is a novel rBMC-based oncolytic immunotherapy. VAX014is a first-in-class tumor-targeted oncolytic agent based on Vaxiion's proprietary rBMC technology. It works by specifically targeting and delivering a novel fast-acting pre-formed oncolytic protein toxin directly to tumor cells that express either α3β1 or α5β1 integrin(s), both commonly found to be selectively expressed in many solid tumor types. The drug is in Phase I stage of clinical trials for the treatment of bladder cancer.

Further product details are provided in the report……..

Bladder Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Bladder Cancer drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Bladder Cancer

There are approx. 80+ key companies which are developing the therapies for Colorectal Cancer. The companies which have their Bladder Cancer drug candidates in the most advanced stage, i.e. phase III include, UroGen Pharma Ltd.

• Phases

Delve Insight’s report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Bladder Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bladder Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III II, I, preclinical and discovery stage. It also analyses Bladder Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bladder Cancer drugs.

Bladder Cancer Report Insights

• Bladder Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Bladder Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Bladder Cancer drugs?
• How many Bladder Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bladder Cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bladder Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Bladder Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• UroGen Pharma Ltd.
• Asieris Pharmaceuticals
• G1 Therapeutics, Inc.
• LintonPharm Co.Ltd.
• Vaxiion Therapeutics
• Merck Sharp & Dohme LLC
• CG Oncology, Inc.
• Ferring Pharmaceuticals
• SURGE Therapeutics
• Halozyme Therapeutics
• ImmunityBio, Inc.
• AstraZeneca
• Spectrum Pharmaceuticals, Inc
• enGene, Inc.
• CicloMed LLC
• Protara Therapeutics
• Hoffmann-La Roche
• CG Oncology, Inc.
• Astellas Pharma Global Development, Inc
• Five Prime Therapeutics, Inc.

Key Products

• UGN-102
• APL 1202
• Trilaciclib
• Catumaxomab
• VAX 014
• Pembrolizumab
• CG0070
• ADSTILADRIN
• STM-416
• Mitomycin C
• BCG+N-803
• Durvalumab
• Apaziquone
• EG-70
• CPX-POM
• TARA-002
• Atezolizumab
• CG0070
• Enfortumab vedotin
• FPA144